ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

Oramed Pharmaceuticals Inc. reported first-quarter 2026 results with no product revenue and a swing to net income of $38.31M versus a net loss of $(7.64) M in the year-ago quarter; diluted EPS was $0.91 for Q1 2026 compared with $(0.19) in Q1 2025.Financial HighlightsRevenue was $0 for Q1 2026, down from $2.0M in Q1 2025.Net income was $38.31M for Q1 2026, compared with a net loss of $(7.64) M in Q1 2025 (improvement of $45.95M).Diluted EPS was $0.91 for Q1 2026, versus $(0.19) in Q1 2025.Business HighlightsRevenue shift: The company recorded no product revenue in Q1 2026 as license-related revenue recognition declined versus $2.0M a year earlier.Portfolio strategy: Oramed transitioned to an active operator of a medical technology portfolio, acquiring controlling stakes and managing clinical and regulatory strategy for portfolio companies.Clinical & R&D: R&D spending was reduced after prior Phase 3 terminations; the company plans to intensify the ORA-D-013-3 trial via OraTech and continues to manage POD™ trials.Strategic transactions: Closed the Lifeward deal transferring POD™ IP and received equity and warrants, plus secured a revenue-share arrangement on ReWalk products.Operational milestones: Invested in Alpha Tau and Lifeward, supported multiple Alpha Tau FDA trials and obtained Japan Shonin approval for Alpha DaRT.Original SEC Filing: ORAMED PHARMACEUTICALS INC. [ ORMP ] - 10-Q - May. 19, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.